Savara appoints Peter Ginsberg as VP of Business Development

Inhaled drug developer Savara has announced the appointment of Peter Ginsberg as VP of Business Development. Ginsberg was most recently VP of Business Development at BioDelivery Sciences International and had previously held business development positions at a number of companies, including United Therapeutics and Surmodics. He also has experience as a biotechnology analyst.

Savara President and Chief Operating Officer Taneli Jouhikainen commented, “We are incredibly pleased to have Peter join our team at this pivotal time in the company’s development. Peter has an impressive track record of generating growth through business development transactions and devising corporate strategy with a specific focus on orphan lung disease opportunities. We see this as a perfect match to Savara’s next phase of development and growth.”

The company recently filed an IND for a study of Molgradex inhaled recombinant human GM-CSF for the treatment of autoimmune pulmonary alveolar proteinosis (PAP).

Read the Savara press release.

Share

published on

December 9-December 11: DDL 2026, Edinburgh, Scotland

April 27-30: RDD Europe 2027, Antibes, France

June 30: RespireX 2027, Boston, MA, USA